Quality-Adjusted Life Years
This graph shows the total number of publications written about "Quality-Adjusted Life Years" by people in the URMC Research Network by year, and whether "Quality-Adjusted Life Years" was a major or minor topic of these publication.
Below are the most recent publications written about "Quality-Adjusted Life Years" by people in Profiles.
-
Noyes K, Bajorska A, Chappel A, Schwid SR, Mehta LR, Weinstock-Guttman B, Holloway RG, Dick AW. Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study. Neurology. 2011 Jul 26; 77(4):355-63.
-
Young KC, Holloway RG, Burgin WS, Benesch CG. A cost-effectiveness analysis of carotid artery stenting compared with endarterectomy. J Stroke Cerebrovasc Dis. 2010 Sep-Oct; 19(5):404-9.
-
Muennig P, Fiscella K, Tancredi D, Franks P. The relative health burden of selected social and behavioral risk factors in the United States: implications for policy. Am J Public Health. 2010 Sep; 100(9):1758-64.
-
Young KC, Awad NA, Johansson M, Gillespie D, Singh MJ, Illig KA. Cost-effectiveness of abdominal aortic aneurysm repair based on aneurysm size. J Vasc Surg. 2010 Jan; 51(1):27-32; discussion 32.
-
Young KC, Teeters JC, Benesch CG, Bisognano JD, Illig KA. Cost-effectiveness of treating resistant hypertension with an implantable carotid body stimulator. J Clin Hypertens (Greenwich). 2009 Oct; 11(10):555-63.
-
Thompson JP, Noyes K, Dorsey ER, Schwid SR, Holloway RG. Quantitative risk-benefit analysis of natalizumab. Neurology. 2008 Jul 29; 71(5):357-64.
-
Holland ML, Huston A, Noyes K. Cost-effectiveness of testing for breast cancer susceptibility genes. Value Health. 2009 Mar-Apr; 12(2):207-16.
-
Franks P, Fiscella K. Reducing disparities downstream: prospects and challenges. J Gen Intern Med. 2008 May; 23(5):672-7.
-
O'Connor AB, Noyes K, Holloway RG. A cost-utility comparison of four first-line medications in painful diabetic neuropathy. Pharmacoeconomics. 2008; 26(12):1045-64.
-
Noyes K, Dick AW, Holloway RG. The implications of using US-specific EQ-5D preference weights for cost-effectiveness evaluation. Med Decis Making. 2007 May-Jun; 27(3):327-34.
